Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1178427

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1178427

NA Pingueculum Drugs Market - Industry Trends and Forecast to 2029

PUBLISHED:
PAGES: 190 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 3500
PDF (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

The North America pingueculum drugs market is projected to register a substantial CAGR of 6.8% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.

Market Segmentation:

North America Pingueculum Drugs Market, By Treatment (Artificial Tears /Topical Lubricants, Steroid Eye Drops, Non-steroidal Anti Inflammatory Drops, and Others), Formulation Type (Eye Drops, Eye Ointments, and Others), Mode of Purchase (Prescription, Over the Counter), Drug Type (Branded, Generics), Population Type (Geriatric, Adults), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the global pingueculum drugs market are:

Rise in the prevalence of pingueculum disease around the globe

Rise in the UV exposure to the individuals due to ozone defect casing pingueculum more frequently

Market Players:

Some of the major players operating in the North America pingueculum drugs market are:

AbbVie Inc.

Akorn Operating Company LLC

Alcon Inc.

Amneal Pharmaceuticals LLC

Bausch & Lomb Incorporated

Bayer AG

Johnson & Johnson Consumer Inc.

Novartis AG

OASIS Medical, Inc.

Prestige Consumer Healthcare Inc.

Santen Pharmaceutical Co.

Similasan Corporation

Laboratoires Thea

Wellona Pharma

Zydus Group

TABLE OF CONTENTS

1 INTRODUCTION 43

  • 1.1 OBJECTIVES OF THE STUDY 43
  • 1.2 MARKET DEFINITION 43
  • 1.3 OVERVIEW OF THE NORTH AMERICA PINGUECULUM DRUGS MARKET 43
  • 1.4 CURRENCY AND PRICING 45
  • 1.5 LIMITATIONS 45
  • 1.6 MARKETS COVERED 46

2 NORTH AMERICA PINGUECULUM DRUGS MARKET: SEGMENTATION 48

  • 2.1 MARKETS COVERED 48
  • 2.2 GEOGRAPHICAL SCOPE 49
  • 2.3 YEARS CONSIDERED FOR THE STUDY 50
  • 2.4 CURRENCY AND PRICING 50
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 51
  • 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 54
  • 2.7 MULTIVARIATE MODELLING 55
  • 2.8 TREATMENT LIFELINE CURVE 55
  • 2.9 DBMR MARKET POSITION GRID 56
  • 2.10 VENDOR SHARE ANALYSIS 58
  • 2.11 MARKET END-USER COVERAGE GRID 59
  • 2.12 SECONDARY SOURCES 60
  • 2.13 ASSUMPTIONS 60

3 EXECUTIVE SUMMARY 61

4 PREMIUM INSIGHTS 64

  • 4.1 EPIDERMIOLOGY 65
  • 4.2 PESTEL ANALYSIS 66
  • 4.3 PORTER'S FIVE FORCES 67
  • 4.4 PIPELINE ANALYSIS FOR THE NORTH AMERICA PINGUECULUM DRUGS MARKET 68
  • 4.5 INDUSTRIAL INSIGHTS: 69
  • 4.6 CONCLUSION: 69

5 NORTH AMERICA PINGUECULUM DRUGS MARKET: REGULATIONS 70

6 MARKET OVERVIEW 73

  • 6.1 DRIVERS 75
    • 6.1.1 RISING PREVALENCE OF PINGUECELA DISORDERS AND OCULAR PAINS 75
    • 6.1.2 RISE IN THE CHRONIC UV RADIATION EXPOSURE DUE TO OZONE DEFECT 75
    • 6.1.3 INCREASING AWARENESS AMONG PEOPLE FOR EYE-RELATED DISEASES 76
    • 6.1.4 RISING OPHTHALMIC EMERGENCIES IN THE GERIATRIC PATIENT 77
  • 6.2 RESTRAINTS 77
    • 6.2.1 STRINGENT RULES & REGULATIONS 77
    • 6.2.2 LACK OF HEALTHCARE FACILITIES FOR EYE TREATMENT 78
  • 6.3 OPPORTUNITIES 79
    • 6.3.1 INITIATIVES AND PLANS TO LESSEN THE PREVALENCE OF EYE ILLNESSES 79
    • 6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 79
    • 6.3.3 INCREASE IN HEALTHCARE SPENDING AND ACCESSIBLE INCOME 80
  • 6.4 CHALLENGES 81
    • 6.4.1 ADVERSE EFFECTS OF STEROID EYE DROPS 81
    • 6.4.2 LACK OF SKILLED OPHTHALMOLOGISTS 82

7 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY TREATMENT 83

  • 7.1 OVERVIEW 84
  • 7.2 ARTIFICIAL TEARS/TOPICAL LUBRICANTS 87
    • 7.2.1 DEMULCENT 87
    • 7.2.2 EMOLLIENTS 87
  • 7.3 STEROID EYE DROPS 88
    • 7.3.1 KETONE STEROIDS 89
      • 7.3.1.1 PREDNISOLONE 89
      • 7.3.1.2 DEXAMETHASONE 89
      • 7.3.1.3 FLUROMETHOLONE 89
      • 7.3.1.4 MEDRYSONE 89
      • 7.3.1.5 RIMEXOLONE 89
      • 7.3.1.6 OTHERS 89
    • 7.3.2 ESTER STEROID (LOTERPREDNOL) 90
  • 7.4 NON-STEROIDAL ANTI-INFLAMMATORY DROPS 90
  • 7.5 OTHERS 90

8 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY FORMULATION 91

  • 8.1 OVERVIEW 92
  • 8.2 EYE DROPS 95
    • 8.2.1 EYE DROPS WITH PRESERVATIVES 95
    • 8.2.2 PRESERVATIVE-FREE EYE DROPS 95
  • 8.3 EYE OINTMENTS 96
    • 8.3.1 WITH PRESERVATIVES 96
    • 8.3.2 PRESERVATIVE-FREE 96
    • 8.3.3 OTHERS 96
  • 8.4 OTHERS 97

9 NORTH AMERICA PINGUECULUM DRUGS MARKET, MODE OF PURCHASE 98

  • 9.1 OVERVIEW 99
  • 9.2 PRESCRIPTION 102
  • 9.3 OVER THE COUNTER (OTC) 102

10 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY DRUGS TYPE 103

  • 10.1 OVERVIEW 104
  • 10.2 BRANDED 107
  • 10.3 GENERICS 107

11 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY POPULATION TYPE 108

  • 11.1 OVERVIEW 109
  • 11.2 GERIATRIC 112
    • 11.2.1 MALE 112
    • 11.2.2 FEMALE 112
  • 11.3 ADULTS 113
    • 11.3.1 MALE 113
    • 11.3.2 FEMALE 113

12 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY END USER 114

  • 12.1 OVERVIEW 115
  • 12.2 HOSPITALS 118
  • 12.3 SPECIALTY CLINICS 118
  • 12.4 HOME HEALTHCARE 119
  • 12.5 OTHERS 119

13 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL 120

  • 13.1 OVERVIEW 121
  • 13.2 RETAIL PHARMACIES 124
  • 13.3 HOSPITAL PHARMACIES 124
  • 13.4 ONLINE PHARMACIES 125
  • 13.5 OTHERS 125

14 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY REGION 126

  • 14.1 NORTH AMERICA 127
    • 14.1.1 U.S. 136
    • 14.1.2 MEXICO 140
    • 14.1.3 CANADA 144

15 NORTH AMERICA PINGUECULUM DRUGS MARKET: COMPANY LANDSCAPE 148

  • 15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 148

16 SWOT ANALYSIS 149

17 COMPANY PROFILE 150

  • 17.1 ALCON INC. 150
    • 17.1.1 COMPANY SNAPSHOT 150
    • 17.1.2 REVENUE ANALYSIS 150
    • 17.1.3 COMPANY SHARE ANALYSIS 151
    • 17.1.4 PRODUCT PORTFOLIO 151
    • 17.1.5 RECENT DEVELOPMENT 151
  • 17.2 ABBVIE INC. 152
    • 17.2.1 COMPANY SNAPSHOT 152
    • 17.2.2 REVENUE ANALYSIS 152
    • 17.2.3 COMPANY SHARE ANALYSIS 153
    • 17.2.4 PRODUCT PORTFOLIO 153
    • 17.2.5 RECENT DEVELOPMENT 154
  • 17.3 BAUSCH & LOMB INCORPORATED 155
    • 17.3.1 COMPANY SNAPSHOT 155
    • 17.3.2 REVENUE ANALYSIS 155
    • 17.3.3 COMPANY SHARE ANALYSIS 156
    • 17.3.4 PRODUCT PORTFOLIO 156
    • 17.3.5 RECENT DEVELOPMENT 157
  • 17.4 BAYER AG 158
    • 17.4.1 COMPANY SNAPSHOT 158
    • 17.4.2 REVENUE ANALYSIS 158
    • 17.4.3 COMPANY SHARE ANALYSIS 159
    • 17.4.4 PRODUCT PORTFOLIO 159
    • 17.4.5 RECENT DEVELOPMENTS 159
  • 17.5 JOHNSON & JOHNSON VISION CARE, INC. 160
    • 17.5.1 COMPANY SNAPSHOT 160
    • 17.5.2 REVENUE ANALYSIS 160
    • 17.5.3 COMPANY SHARE ANALYSIS 161
    • 17.5.4 PRODUCT PORTFOLIO 161
    • 17.5.5 RECENT DEVELOPMENT 161
  • 17.6 AKORN OPERATING COMPANY LLC 162
    • 17.6.1 COMPANY SNAPSHOT 162
    • 17.6.2 . PRODUCT PORTFOLIO 162
    • 17.6.3 RECENT DEVELOPMENT 162
  • 17.7 AMNEAL PHARMACEUTICALS LLC. 163
    • 17.7.1 COMPANY SNAPSHOT 163
    • 17.7.2 REVENUE ANALYSIS 163
    • 17.7.3 PRODUCT PORTFOLIO 164
    • 17.7.4 RECENT DEVELOPMENTS 164
  • 17.8 EYERIS VISIONCARE PVT. LTD. 165
    • 17.8.1 COMPANY SNAPSHOT 165
    • 17.8.2 PRODUCT PORTFOLIO 165
    • 17.8.3 RECENT DEVELOPMENTS 166
  • 17.9 LABORATOIRES THEA 167
    • 17.9.1 COMPANY SNAPSHOT 167
    • 17.9.2 PRODUCT PORTFOLIO 167
    • 17.9.3 RECENT DEVELOPMENT 168
  • 17.10 MAYA BIOTECH PRIVATE LIMITED 169
    • 17.10.1 COMPANY SNAPSHOT 169
    • 17.10.2 PRODUCT PORTFOLIO 169
    • 17.10.3 RECENT DEVELOPMENTS 170
  • 17.11 NOVARTIS AG 171
    • 17.11.1 COMPANY SNAPSHOT 171
    • 17.11.2 REVENUE ANALYSIS 171
    • 17.11.3 PRODUCT PORTFOLIO 172
    • 17.11.4 RECENT DEVELOPMENT 172
  • 17.12 OASIS MEDICAL, INC. 173
    • 17.12.1 COMPANY SNAPSHOT 173
    • 17.12.2 PRODUCT PORTFOLIO 173
    • 17.12.3 RECENT DEVELOPMENT 173
  • 17.13 PRESTIGE CONSUMER HEALTHCARE, INC. 174
    • 17.13.1 COMPANY SNAPSHOT 174
    • 17.13.2 PRODUCT PORTFOLIO 175
    • 17.13.3 RECENT DEVELOPMENT 175
  • 17.14 SAGER PHARMA 176
    • 17.14.1 COMPANY SNAPSHOT 176
    • 17.14.2 PRODUCT PORTFOLIO 176
    • 17.14.3 RECENT DEVELOPMENTS 176
  • 17.15 SANTEN PHARMACEUTICAL CO., LTD. 177
    • 17.15.1 COMPANY SNAPSHOT 177
    • 17.15.2 REVENUE ANALYSIS 177
    • 17.15.3 PRODUCT PORTFOLIO 178
    • 17.15.4 RECENT DEVELOPMENTS 178
  • 17.16 SIMILASAN CORPORATION 179
    • 17.16.1 COMPANY SNAPSHOT 179
    • 17.16.2 PRODUCT PORTFOLIO 179
    • 17.16.3 RECENT DEVELOPMENTS 179
  • 17.17 SPECTRA VISION CARE 180
    • 17.17.1 COMPANY SNAPSHOT 180
    • 17.17.2 PRODUCT PORTFOLIO 180
    • 17.17.3 RECENT DEVELOPMENTS 181
  • 17.18 SYLENTIS 182
    • 17.18.1 COMPANY SNAPSHOT 182
    • 17.18.2 PRODUCT PORTFOLIO 182
    • 17.18.3 RECENT DEVELOPMENTS 182
  • 17.19 WELLONA PHARMA 183
    • 17.19.1 COMPANY SNAPSHOT 183
    • 17.19.2 PRODUCT PORTFOLIO 183
    • 17.19.3 RECENT DEVELOPMENTS 183
  • 17.20 ZYDUS GROUP 184
    • 17.20.1 COMPANY SNAPSHOT 184
    • 17.20.2 REVENUE ANALYSIS 184
    • 17.20.3 PRODUCT PORTFOLIO 185
    • 17.20.4 RECENT DEVELOPMENTS 185

18 QUESTIONNAIRE 186

19 RELATED REPORTS 190

LIST OF TABLES

  • TABLE 1 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 60
  • TABLE 2 NORTH AMERICA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 61
  • TABLE 3 NORTH AMERICA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION) 61
  • TABLE 4 NORTH AMERICA STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 62
  • TABLE 5 NORTH AMERICA STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION) 62
  • TABLE 6 NORTH AMERICA KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION) 63
  • TABLE 7 NORTH AMERICA NON-STEROIDAL ANTI-INFLAMMATORY DROPS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 64
  • TABLE 8 NORTH AMERICA OTHERS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 64
  • TABLE 9 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 68
  • TABLE 10 NORTH AMERICA EYE DROPS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 69
  • TABLE 11 NORTH AMERICA EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 69
  • TABLE 12 NORTH AMERICA EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 70
  • TABLE 13 NORTH AMERICA EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 70
  • TABLE 14 NORTH AMERICA OTHERS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 71
  • TABLE 15 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION) 75
  • TABLE 16 NORTH AMERICA PRESCRIPTION IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 76
  • TABLE 17 NORTH AMERICA OVER THE COUNTER (OTC) IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 76
  • TABLE 18 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION) 80
  • TABLE 19 NORTH AMERICA BRANDED IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 81
  • TABLE 20 NORTH AMERICA GENERICS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 81
  • TABLE 21 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 85
  • TABLE 22 NORTH AMERICA GERIATRIC IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 86
  • TABLE 23 NORTH AMERICA GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 86
  • TABLE 24 NORTH AMERICA ADULTS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 87
  • TABLE 25 NORTH AMERICA ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 87
  • TABLE 26 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION) 91
  • TABLE 27 NORTH AMERICA HOSPITALS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 92
  • TABLE 28 NORTH AMERICA SPECIALTY CLINICS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 92
  • TABLE 29 NORTH AMERICA HOME HEALTHCARE IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 93
  • TABLE 30 NORTH AMERICA OTHERS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 93
  • TABLE 31 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 97
  • TABLE 32 NORTH AMERICA RETAIL PHARMACIES IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 98
  • TABLE 33 NORTH AMERICA HOSPITAL PHARMACIES IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 98
  • TABLE 34 NORTH AMERICA ONLINE PHARMACIES IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 99
  • TABLE 35 NORTH AMERICA OTHERS IN PINGUECULUM DRUGS MARKET, BY REGION, 2020-2029 (USD MILLION) 99
  • TABLE 36 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 106
  • TABLE 37 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 106
  • TABLE 38 NORTH AMERICA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION) 106
  • TABLE 39 NORTH AMERICA STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION) 106
  • TABLE 40 NORTH AMERICA KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION) 107
  • TABLE 41 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 107
  • TABLE 42 NORTH AMERICA EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 107
  • TABLE 43 NORTH AMERICA EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 108
  • TABLE 44 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION) 108
  • TABLE 45 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION) 108
  • TABLE 46 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 108
  • TABLE 47 NORTH AMERICA GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 108
  • TABLE 48 NORTH AMERICA ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 109
  • TABLE 49 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION) 109
  • TABLE 50 NORTH AMERICA PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 109
  • TABLE 51 U.S. PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 110
  • TABLE 52 U.S. ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION) 110
  • TABLE 53 U.S. STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION) 110
  • TABLE 54 U.S. KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION) 111
  • TABLE 55 U.S. PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 111
  • TABLE 56 U.S. EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 111
  • TABLE 57 U.S. EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 111
  • TABLE 58 U.S. PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION) 112
  • TABLE 59 U.S. PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION) 112
  • TABLE 60 U.S. PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 112
  • TABLE 61 U.S. GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 112
  • TABLE 62 U.S. ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 112
  • TABLE 63 U.S. PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION) 113
  • TABLE 64 U.S. PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 113
  • TABLE 65 MEXICO PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 114
  • TABLE 66 MEXICO ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION) 114
  • TABLE 67 MEXICO STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION) 114
  • TABLE 68 MEXICO KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION) 115
  • TABLE 69 MEXICO PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 115
  • TABLE 70 MEXICO EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 115
  • TABLE 71 MEXICO EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 115
  • TABLE 72 MEXICO PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION) 116
  • TABLE 73 MEXICO PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION) 116
  • TABLE 74 MEXICO PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 116
  • TABLE 75 MEXICO GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 116
  • TABLE 76 MEXICO ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 116
  • TABLE 77 MEXICO PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION) 117
  • TABLE 78 MEXICO PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 117
  • TABLE 79 CANADA PINGUECULUM DRUGS MARKET, BY TREATMENT, 2020-2029 (USD MILLION) 118
  • TABLE 80 CANADA ARTIFICIAL TEARS/TOPICAL LUBRICANTS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION) 118
  • TABLE 81 CANADA STEROID EYE DROPS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION) 118
  • TABLE 82 CANADA KETONE STEROIDS IN PINGUECULUM DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION) 119
  • TABLE 83 CANADA PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 119
  • TABLE 84 CANADA EYE DROPS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 119
  • TABLE 85 CANADA EYE OINTMENTS IN PINGUECULUM DRUGS MARKET, BY FORMULATION, 2020-2029 (USD MILLION) 119
  • TABLE 86 CANADA PINGUECULUM DRUGS MARKET, BY MODE OF PURCHASE, 2020-2029 (USD MILLION) 120
  • TABLE 87 CANADA PINGUECULUM DRUGS MARKET, BY DRUGS TYPE, 2020-2029 (USD MILLION) 120
  • TABLE 88 CANADA PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 120
  • TABLE 89 CANADA GERIATRIC IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 120
  • TABLE 90 CANADA ADULTS IN PINGUECULUM DRUGS MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION) 120
  • TABLE 91 CANADA PINGUECULUM DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION) 121
  • TABLE 92 CANADA PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION) 121

LIST OF FIGURES

  • FIGURE 1 NORTH AMERICA PINGUECULUM DRUGS MARKET: SEGMENTATION 21
  • FIGURE 2 NORTH AMERICA PINGUECULUM DRUGS MARKET: DATA TRIANGULATION 24
  • FIGURE 3 NORTH AMERICA PINGUECULUM DRUGS MARKET: DROC ANALYSIS 25
  • FIGURE 4 NORTH AMERICA PINGUECULUM DRUGS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS 26
  • FIGURE 5 NORTH AMERICA PINGUECULUM DRUGS MARKET: COMPANY RESEARCH ANALYSIS 26
  • FIGURE 6 NORTH AMERICA PINGUECULUM DRUGS MARKET: INTERVIEW DEMOGRAPHICS 27
  • FIGURE 7 NORTH AMERICA PINGUECULUM DRUGS MARKET: DBMR POSITION GRID 29
  • FIGURE 8 NORTH AMERICA PINGUECULUM DRUGS MARKET: VENDOR SHARE ANALYSIS 31
  • FIGURE 9 NORTH AMERICA PINGUECULUM DRUGS MARKET: END USER COVERAGE GRID 32
  • FIGURE 10 NORTH AMERICA PINGUECULUM DRUGS MARKET: SEGMENTATION 36
  • FIGURE 11 INCREASING PREVALENCE OF OPHTHALMIC DISORDERS AND THE RISE IN THE GERIATRIC POPULATION ARE EXPECTED TO DRIVE THE NORTH AMERICA PINGUECULUM DRUGS MARKET GROWTH FROM 2022 TO 2029 37
  • FIGURE 12 ARTIFICIAL TEARS/TOPICAL LUBRICANTS SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE NORTH AMERICA PINGUECULUM DRUGS MARKET FROM 2022 & 2029 37
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA PINGUECULUM DRUGS MARKET 47
  • FIGURE 14 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY TREATMENT, 2021 57
  • FIGURE 15 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY TREATMENT, 2022-2029 (USD MILLION) 58
  • FIGURE 16 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY TREATMENT, CAGR (2022-2029) 58
  • FIGURE 17 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY TREATMENT, LIFELINE CURVE 59
  • FIGURE 18 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY FORMULATION, 2021 65
  • FIGURE 19 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY FORMULATION, 2022-2029 (USD MILLION) 66
  • FIGURE 20 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY FORMULATION, CAGR (2022-2029) 66
  • FIGURE 21 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY FORMULATION, LIFELINE CURVE 67
  • FIGURE 22 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY MODE OF PURCHASE, 2021 72
  • FIGURE 23 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY MODE OF PURCHASE, 2022-2029 (USD MILLION) 73
  • FIGURE 24 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY MODE OF PURCHASE, CAGR (2022-2029) 73
  • FIGURE 25 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY MODE OF PURCHASE, LIFELINE CURVE 74
  • FIGURE 26 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DRUGS TYPE, 2021 77
  • FIGURE 27 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DRUGS TYPE, 2022-2029 (USD MILLION) 78
  • FIGURE 28 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DRUGS TYPE, CAGR (2022-2029) 78
  • FIGURE 29 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DRUGS TYPE, LIFELINE CURVE 79
  • FIGURE 30 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY POPULATION TYPE, 2021 82
  • FIGURE 31 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY POPULATION TYPE, 2022-2029 (USD MILLION) 83
  • FIGURE 32 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY POPULATION TYPE, CAGR (2022-2029) 83
  • FIGURE 33 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY POPULATION TYPE, LIFELINE CURVE 84
  • FIGURE 34 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY END USER, 2021 88
  • FIGURE 35 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY END USER, 2022-2029 (USD MILLION) 89
  • FIGURE 36 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY END USER, CAGR (2022-2029) 89
  • FIGURE 37 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY END USER, LIFELINE CURVE 90
  • FIGURE 38 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021 94
  • FIGURE 39 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 95
  • FIGURE 40 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 95
  • FIGURE 41 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 96
  • FIGURE 42 NORTH AMERICA PINGUECULUM DRUGS MARKET: SNAPSHOT (2021) 101
  • FIGURE 43 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY COUNTRY (2021) 103
  • FIGURE 44 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY COUNTRY (2022 & 2029) 103
  • FIGURE 45 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY COUNTRY (2021 & 2029) 104
  • FIGURE 46 NORTH AMERICA PINGUECULUM DRUGS MARKET: BY TREATMENT (2022-2029) 104
  • FIGURE 47 NORTH AMERICA PINGUECULUM DRUGS MARKET: COMPANY SHARE 2021 (%) 121
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!